Free Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement Case Study Solution | Assignment Help

Harvard Case - Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement

"Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement" Harvard business case study is written by Julie Rosenberg, Iman Ahmad, Nour Sharara, Rebecca Weintraub. It deals with the challenges in the field of Business & Government Relations. The case study is 31 page(s) long and it was first published on : Sep 1, 2020

At Fern Fort University, we recommend a multi-faceted approach to advancing the new drug for global maternal health. This approach leverages a tripartite agreement between the pharmaceutical company, a non-profit organization, and a consortium of developing countries, focusing on a combination of public-private partnerships, government policy and regulation, and corporate social responsibility. This strategy aims to ensure equitable access to the drug, promote sustainable development, and foster long-term economic growth in developing countries.

2. Background

The case study focuses on a pharmaceutical company, MedTech, which has developed a groundbreaking drug that can significantly reduce maternal mortality rates. The company faces the challenge of bringing this drug to market in developing countries, where access to healthcare is limited. The case explores the complexities of navigating international business, government regulations, and social responsibility in this context.

The main protagonists are:

  • MedTech: A pharmaceutical company with a new drug that can revolutionize maternal health.
  • Global Health Initiative (GHI): A non-profit organization dedicated to improving healthcare in developing countries.
  • Consortium of Developing Countries: A group of nations committed to improving their healthcare systems and reducing maternal mortality.

3. Analysis of the Case Study

The case study presents a complex scenario that requires a strategic approach. We can analyze the case using a framework that considers the following aspects:

  • Political and Regulatory Environment: The success of the drug's launch depends heavily on the political and regulatory landscape in developing countries. Factors such as government policies, trade agreements, intellectual property rights, and foreign direct investment policies will significantly influence the project's feasibility.
  • Economic Considerations: The economic situation in developing countries, including poverty, economic growth, and exchange rates, will impact the affordability and accessibility of the drug.
  • Social and Ethical Implications: The project must address the ethical considerations surrounding access to healthcare, corporate social responsibility, and the potential impact on health and behavioral science.
  • Competitive Landscape: MedTech needs to consider the competitive landscape, including potential competitors, industry regulation, and antitrust legislation.
  • Operational Challenges: The project will require a robust operational strategy, including logistics, supply chain management, and infrastructure development.

4. Recommendaations

  1. Tripartite Agreement: MedTech should formalize a tripartite agreement with GHI and the consortium of developing countries. This agreement should outline the roles and responsibilities of each party, including:
    • MedTech: Provide the drug at a subsidized price, invest in local manufacturing facilities, and support capacity building initiatives.
    • GHI: Facilitate the distribution and administration of the drug, conduct awareness campaigns, and provide training for healthcare professionals.
    • Consortium of Developing Countries: Implement policies that support the drug's accessibility, including tax incentives, government subsidies, and regulatory streamlining.
  2. Government Relations: MedTech should actively engage with the governments of developing countries to build strong relationships and ensure regulatory compliance. This includes:
    • Lobbying strategies: Advocate for policies that support the drug's access and distribution.
    • Corporate political activity: Participate in relevant policy discussions and engage with government officials.
    • Political risk analysis: Monitor political developments and anticipate potential challenges.
  3. Social Impact Strategy: MedTech should develop a comprehensive social impact strategy that addresses the ethical considerations of the project. This includes:
    • Corporate social responsibility (CSR): Invest in community development initiatives and support local healthcare infrastructure.
    • Stakeholder engagement: Engage with local communities, healthcare providers, and other stakeholders to ensure the project aligns with their needs.
  4. Financial Sustainability: MedTech should explore innovative financing mechanisms to ensure the long-term sustainability of the project. This includes:
    • Public-private partnerships: Partner with governments and non-profit organizations to secure funding.
    • Investment management: Explore impact investing opportunities to attract private capital.
    • Financial markets: Access international financial markets to secure debt financing.

5. Basis of Recommendaations

These recommendations are based on the following considerations:

  • Core competencies and consistency with mission: The tripartite agreement aligns with MedTech's mission to improve global health and its core competency in drug development.
  • External customers and internal clients: The recommendations address the needs of external customers (patients in developing countries) and internal clients (MedTech employees, investors, and stakeholders).
  • Competitors: The recommendations consider the competitive landscape and aim to create a sustainable advantage for MedTech.
  • Attractiveness ' quantitative measures if applicable (e.g., NPV, ROI, break-even, payback): While specific financial projections are not provided in the case study, the recommendations aim to maximize the project's social and economic impact.
  • Assumptions: The recommendations assume that MedTech is committed to social responsibility and is willing to invest in long-term partnerships.

6. Conclusion

By implementing these recommendations, MedTech can successfully advance its new drug to improve global maternal health. This approach will leverage the strengths of public-private partnerships, government policy and regulation, and corporate social responsibility to ensure equitable access to the drug, promote sustainable development, and foster long-term economic growth in developing countries.

7. Discussion

Other alternatives not selected include:

  • Exclusive licensing agreement: MedTech could license the drug to a local pharmaceutical company in each developing country. However, this approach might not guarantee equitable access and could lead to higher prices.
  • Direct sales to governments: MedTech could sell the drug directly to governments in developing countries. However, this approach might be challenging due to bureaucratic hurdles and limited government budgets.

Risks and key assumptions of the recommendation:

  • Political instability: Political instability in developing countries could disrupt the project's implementation.
  • Regulatory changes: Changes in government regulations could impact the drug's accessibility.
  • Financial challenges: The project might face financial challenges due to limited resources in developing countries.

8. Next Steps

  1. Negotiate the tripartite agreement: MedTech should initiate negotiations with GHI and the consortium of developing countries to finalize the tripartite agreement.
  2. Develop a social impact strategy: MedTech should develop a comprehensive social impact strategy that outlines its commitment to CSR and stakeholder engagement.
  3. Secure funding: MedTech should explore various funding sources, including public-private partnerships and impact investing, to secure the necessary financial resources.
  4. Implement pilot programs: MedTech should implement pilot programs in selected developing countries to test the project's effectiveness and identify areas for improvement.

By taking these steps, MedTech can successfully launch its new drug and make a significant contribution to improving global maternal health.

Hire an expert to write custom solution for HBR Business Government case study - Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement

more similar case solutions ...

Case Description

The case traces the development of a tripartite initiative-known as Project Carbetocin Hemorrhage Prevention (CHAMPION)-between Merck for Mothers, Ferring Pharmaceuticals, and the World Health Organization (WHO) that formed to help prevent postpartum hemorrhage (PPH), one of the leading causes of maternal mortality globally. After providing background on the global burden of maternal mortality and global efforts to amplify the issue and improve outcomes, the case highlights clinical trial results that show administering quality uterotonics (drugs that induce uterine contractions) immediately following childbirth was the most important measure in preventing PPH. However, the recommended therapy-oxytocin-was often compromised at the point of delivery in areas with unreliable cold-chain infrastructure, due to its sensitivity to heat. In this context, the case details how Project CHAMPION brought together three unique actors to advance the development and distribution of a uterotonic that could withstand temperature changes. The case describes negotiations around the undertaking, the large-scale clinical trial of the new drug-heat-stable carbetocin-that took place across 10 countries, enrolling 30,000 women, and the steps undertaken to prepare diverse markets for its debut. The case reveals tension between the mid-size pharmaceutical company, the multilateral World Health Organization, and Merck's Merck for Mothers initiative. The case ends as a pandemic explodes onto the world stage in 2020, with Project CHAMPION team members wondering how the dilemmas, decisions, and dynamics they navigated could inform emerging COVID-19 vaccine discovery and development efforts working with urgency.

🎓 Struggling with term papers, essays, or Harvard case studies? Look no further! Fern Fort University offers top-quality, custom-written solutions tailored to your needs. Boost your grades and save time with expertly crafted content. Order now and experience academic excellence! 🌟📚 #MBA #HarvardCaseStudies #CustomEssays #AcademicSuccess #StudySmart Write my custom case study solution for Harvard HBR case - Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement

Hire an expert to write custom solution for HBR Business Government case study - Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement

Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement FAQ

What are the qualifications of the writers handling the "Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement" case study?

Our writers hold advanced degrees in their respective fields, including MBAs and PhDs from top universities. They have extensive experience in writing and analyzing complex case studies such as " Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement ", ensuring high-quality, academically rigorous solutions.

How do you ensure confidentiality and security in handling client information?

We prioritize confidentiality by using secure data encryption, access controls, and strict privacy policies. Apart from an email, we don't collect any information from the client. So there is almost zero risk of breach at our end. Our financial transactions are done by Paypal on their website so all your information is very secure.

What is Fern Fort Univeristy's process for quality control and proofreading in case study solutions?

The Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement case study solution undergoes a rigorous quality control process, including multiple rounds of proofreading and editing by experts. We ensure that the content is accurate, well-structured, and free from errors before delivery.

Where can I find free case studies solution for Harvard HBR Strategy Case Studies?

At Fern Fort University provides free case studies solutions for a variety of Harvard HBR case studies. The free solutions are written to build "Wikipedia of case studies on internet". Custom solution services are written based on specific requirements. If free solution helps you with your task then feel free to donate a cup of coffee.

I’m looking for Harvard Business Case Studies Solution for Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement. Where can I get it?

You can find the case study solution of the HBR case study "Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement" at Fern Fort University.

Can I Buy Case Study Solution for Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement & Seek Case Study Help at Fern Fort University?

Yes, you can order your custom case study solution for the Harvard business case - "Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement" at Fern Fort University. You can get a comprehensive solution tailored to your requirements.

Can I hire someone only to analyze my Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement solution? I have written it, and I want an expert to go through it.

🎓 Struggling with term papers, essays, or Harvard case studies? Look no further! Fern Fort University offers top-quality, custom-written solutions tailored to your needs. Boost your grades and save time with expertly crafted content. Order now and experience academic excellence! 🌟📚 #MBA #HarvardCaseStudies #CustomEssays #AcademicSuccess #StudySmart Pay an expert to write my HBR study solution for the case study - Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement

Where can I find a case analysis for Harvard Business School or HBR Cases?

You can find the case study solution of the HBR case study "Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement" at Fern Fort University.

Which are some of the all-time best Harvard Business Review Case Studies?

Some of our all time favorite case studies are -

Can I Pay Someone To Solve My Case Study - "Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement"?

Yes, you can pay experts at Fern Fort University to write a custom case study solution that meets all your professional and academic needs.

Do I have to upload case material for the case study Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement to buy a custom case study solution?

We recommend to upload your case study because Harvard HBR case studies are updated regularly. So for custom solutions it helps to refer to the same document. The uploading of specific case materials for Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement ensures that the custom solution is aligned precisely with your needs. This helps our experts to deliver the most accurate, latest, and relevant solution.

What is a Case Research Method? How can it be applied to the Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement case study?

The Case Research Method involves in-depth analysis of a situation, identifying key issues, and proposing strategic solutions. For "Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement" case study, this method would be applied by examining the case’s context, challenges, and opportunities to provide a robust solution that aligns with academic rigor.

"I’m Seeking Help with Case Studies,” How can Fern Fort University help me with my case study assignments?

Fern Fort University offers comprehensive case study solutions, including writing, analysis, and consulting services. Whether you need help with strategy formulation, problem-solving, or academic compliance, their experts are equipped to assist with your assignments.

Achieve academic excellence with Fern Fort University! 🌟 We offer custom essays, term papers, and Harvard HBR business case studies solutions crafted by top-tier experts. Experience tailored solutions, uncompromised quality, and timely delivery. Elevate your academic performance with our trusted and confidential services. Visit Fern Fort University today! #AcademicSuccess #CustomEssays #MBA #CaseStudies

How do you handle tight deadlines for case study solutions?

We are adept at managing tight deadlines by allocating sufficient human resources and prioritizing urgent projects. Our team works efficiently without compromising quality, ensuring that even last-minute requests are delivered on time

What if I need revisions or edits after receiving the case study solution?

We offer free revisions to ensure complete client satisfaction. If any adjustments are needed, our team will work closely with you to refine the solution until it meets your expectations.

How do you ensure that the case study solution is plagiarism-free?

All our case study solutions are crafted from scratch and thoroughly checked using advanced plagiarism detection software. We guarantee 100% originality in every solution delivered

How do you handle references and citations in the case study solutions?

We follow strict academic standards for references and citations, ensuring that all sources are properly credited according to the required citation style (APA, MLA, Chicago, etc.).

Hire an expert to write custom solution for HBR Business Government case study - Advancing a New Drug to Improve Global Maternal Health Through a Tripartite Agreement




Referrences & Bibliography for SWOT Analysis | SWOT Matrix | Strategic Management

1. Andrews, K. R. (1980). The concept of corporate strategy. Harvard Business Review, 61(3), 139-148.

2. Ansoff, H. I. (1957). Strategies for diversification. Harvard Business Review, 35(5), 113-124.

3. Brandenburger, A. M., & Nalebuff, B. J. (1995). The right game: Use game theory to shape strategy. Harvard Business Review, 73(4), 57-71.

4. Christensen, C. M., & Raynor, M. E. (2003). Why hard-nosed executives should care about management theory. Harvard Business Review, 81(9), 66-74.

5. Christensen, C. M., & Raynor, M. E. (2003). The innovator's solution: Creating and sustaining successful growth. Harvard Business Review Press.

6. D'Aveni, R. A. (1994). Hypercompetition: Managing the dynamics of strategic maneuvering. Harvard Business Review Press.

7. Ghemawat, P. (1991). Commitment: The dynamic of strategy. Harvard Business Review, 69(2), 78-91.

8. Ghemawat, P. (2002). Competition and business strategy in historical perspective. Business History Review, 76(1), 37-74.

9. Hamel, G., & Prahalad, C. K. (1990). The core competence of the corporation. Harvard Business Review, 68(3), 79-91.

10. Kaplan, R. S., & Norton, D. P. (1992). The balanced scorecard--measures that drive performance. Harvard Business Review, 70(1), 71-79.

11. Kim, W. C., & Mauborgne, R. (2004). Blue ocean strategy. Harvard Business Review, 82(10), 76-84.

12. Kotter, J. P. (1995). Leading change: Why transformation efforts fail. Harvard Business Review, 73(2), 59-67.

13. Mintzberg, H., Ahlstrand, B., & Lampel, J. (2008). Strategy safari: A guided tour through the wilds of strategic management. Harvard Business Press.

14. Porter, M. E. (1979). How competitive forces shape strategy. Harvard Business Review, 57(2), 137-145.

15. Porter, M. E. (1980). Competitive strategy: Techniques for analyzing industries and competitors. Simon and Schuster.

16. Porter, M. E. (1985). Competitive advantage: Creating and sustaining superior performance. Free Press.

17. Prahalad, C. K., & Hamel, G. (1990). The core competence of the corporation. Harvard Business Review, 68(3), 79-91.

18. Rumelt, R. P. (1979). Evaluation of strategy: Theory and models. Strategic Management Journal, 1(1), 107-126.

19. Rumelt, R. P. (1984). Towards a strategic theory of the firm. Competitive Strategic Management, 556-570.

20. Teece, D. J., Pisano, G., & Shuen, A. (1997). Dynamic capabilities and strategic management. Strategic Management Journal, 18(7), 509-533.